Get the Stockscreener App
8.02
1.35%
-0.11
After Hours:
8.02
Instil Bio Inc stock is traded at $8.02, with a volume of 59,825.
It is down -1.35% in the last 24 hours and down -9.68% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$8.13
Open:
$8.14
24h Volume:
59,825
Relative Volume:
1.78
Market Cap:
$54.39M
Revenue:
-
Net Income/Loss:
$-71.37M
P/E Ratio:
-0.7441
EPS:
-10.7782
Net Cash Flow:
$-46.62M
1W Performance:
-0.99%
1M Performance:
-9.68%
6M Performance:
-34.26%
1Y Performance:
-52.54%
1-Day Range:
$8.02
$8.22
1-Week Range:
$8.00
$8.234
52-Week Range:
$5.67
$42.79
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
8.02 | 55.14M | 0 | -71.37M | -46.62M | -10.78 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Perform |
| Apr-12-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
Trading Systems Reacting to (TIL) Volatility - Stock Traders Daily
Instil Bio (TIL) Q4 2025 Beat: Revenue $N/A, EPS Exceeds by SignificantMargin Improvement - newser.com
Instil Bio, Inc. Reports First Quarter 2026 Financial Results – 8-K Filing Details and Key Highlights - Minichart
Instil Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Instil Bio, Inc. 1Q 2026: Net loss $4.2M, EPS $(0.62) — 10-Q Summary - TradingView
Instil Bio Releases Q1 2026 Financial Results - AlphaStreet
Instil Bio (NASDAQ: TIL) cuts Q1 loss as 2024 loan and going concern risk loom - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027 - Stock Titan
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
BRIEF-Instil Bio Q1 Basic EPS USD -0.62 - TradingView
Instil Bio evaluates new drug deals, $74.7M cash lasts past 2027 - Stock Titan
TradingKey - TradingKey
MSN Money - MSN
Why Instil Bio (TIL) deserves a deeper look right now (Smart Money Flows) 2026-05-08AI Powered Stock Picks - newser.com
Instil Bio Inc expected to post a loss of 59 cents a shareEarnings Preview - TradingView
How Instil Bio Inc. (TIL) Affects Rotational Strategy Timing - Stock Traders Daily
TIL Technical Analysis | Trend, Signals & Chart Patterns | INSTIL BIO INC (NASDAQ:TIL) - ChartMill
The R&D spending story behind Instil Bio (TIL) innovation | Instil Bio posts 41% EPS beat, narrower loss, no revenueDebt/EBITDA - newser.com
Key Growth Drivers | Instil Bio posts 40.9% EPS beat topping analyst estimatesConsensus Forecast - newser.com
(TIL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
[ARS] Instil Bio, Inc. SEC Filing - Stock Titan
Instil Bio (NASDAQ: TIL) sets 2026 vote and replaces Deloitte - Stock Titan
TIL Instil Bio delivers strong Q4 2025 EPS upside versus analyst estimates, shares edge slightly higher in today’s session.Market Expert Watchlist - newser.com
TIL (Instil Bio Inc.) posts narrower Q4 2025 loss than consensus estimates, shares dip modestly in muted market reaction.Viral Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Instil Bio, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
TIL Ownership | INSTIL BIO INC (NASDAQ:TIL) - ChartMill
Instil Bio (TIL) Stock Wall Street Rating (+0.11%) 2026-04-16Community Trade Ideas - Xã Thanh Hà
Responsive Playbooks and the TIL Inflection - Stock Traders Daily
Instil Bio (TIL) Price Target Increased by 24.53% to 67.32 - MSN
Breakout Move: Is Instil Bio Inc gaining market share2026 Setups & Community Verified Watchlist Alerts - baoquankhu1.vn
Will Instil Bio (TIL) Stock Outperform S&P 500 | Price at $7.99, Down 0.50%Risk Reward Ratio - newser.com
Instil Bio appoints RSM US as new auditor, replacing Deloitte & Touche - Investing.com India
Instil Bio appoints RSM US as new auditor, replacing Deloitte & Touche By Investing.com - Investing.com South Africa
Instil Bio (TIL) replaces Deloitte with RSM as independent auditor - Stock Titan
Understanding the Setup: (TIL) and Scalable Risk - Stock Traders Daily
TIL Technical Analysis & Stock Price Forecast - Intellectia AI
TIL PE Ratio & Valuation, Is TIL Overvalued - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Aug Levels: Is Instil Bio Inc forming bullish engulfing patterns2026 Institutional & Capital Efficient Trading Techniques - baoquankhu1.vn
Instil Bio Faces Heightened Cybersecurity Threats as Data Breach Risks Jeopardize Clinical Trials and Long-Term Strategy - TipRanks
Instil Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Instil Bio (NASDAQ: TIL) ends all R&D and warns on going concern - Stock Titan
Instil Bio 2025 10-K: $(71.4)M net loss, $(10.70) loss per share - TradingView
Instil Bio Q4 net loss per share narrows - TradingView
BRIEF-Instil Bio Q4 Basic EPS USD -1.21 - TradingView
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Globe and Mail
Bull Run: What analysts say about Instil Bio Inc stockMarket Volume Summary & Accurate Buy Signal Alerts - baoquankhu1.vn
The Technical Signals Behind (TIL) That Institutions Follow - Stock Traders Daily
If You Invested $1,000 in Instil Bio, Inc. (TIL) - Stock Titan
Instil Bio, Inc.: Fundamental Analysis and Financial Ratings | 5GT0 | US45783C2008 - marketscreener.com
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Instil Bio Inc Stock (TIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Laumas Sandeep | CFO and CBO |
Sep 10 '25 |
Sale |
23.39 |
30,000 |
701,667 |
0 |
1.19%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):